Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 May;11(3):162-9.
doi: 10.1007/s11940-009-0019-3.

Drug-induced parkinsonism

Affiliations

Drug-induced parkinsonism

Frandy Susatia et al. Curr Treat Options Neurol. 2009 May.

Abstract

Drug-induced parkinsonism (DIP) is condition that mimics Parkinson's disease. Characterized mainly by rigidity and bradykinesia, it has less prominent tremor and gait instability. DIP is generally caused by lipophilic drugs that "block" dopamine D2 receptors in the brain, although presynaptic dopamine depletion, false transmitters, mitochondrial respiratory chain dysfunction, and overactivity in the gamma-aminobutyric acid (GABA)ergic system or cholinomimetic action have also been postulated as possible mechanisms. The onset of DIP is acute to subacute. It is more common in women and has a bimodal age distribution. Other diseases that can resemble DIP include neuropsychiatric conditions (eg, depression, negative symptoms of schizophrenia) and Wilson's disease. Physicians may be able to prevent DIP by prescribing neuroleptic agents appropriately and with caution. The risk of DIP is presumably lower with the use of "atypical" antipsychotic agents but it is not eliminated, especially in those most vulnerable to parkinsonism (eg, the elderly or cognitively impaired). The best treatment is discontinuation of the provoking medication. Prospective studies are needed to further define the mechanism of DIP, identify individual susceptibility, determine the impact of atypical antipsychotic agents, and develop further treatment options for those unable to stop the offending agent.

PubMed Disclaimer

References

    1. Neurology. 2008 Feb 19;70(8):e32-4 - PubMed
    1. Neuroreport. 2002 May 7;13(6):831-5 - PubMed
    1. Mov Disord. 2002 Nov;17(6):1354-9 - PubMed
    1. Ann Med Psychol (Paris). 1954 Dec;112(2 5):737-44 - PubMed
    1. Expert Opin Drug Saf. 2005 Jan;4(1):91-102 - PubMed

LinkOut - more resources